The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreAs Seen in nocamels.com
An Israeli medtech company whose novel therapy freezes and destroys malignant tumors has announced positive results in a trial of breast cancer patients.
IceCure Medical (opens in a new tab)’s ProSense system uses extremely cold liquid (cryoablation) to freeze and destroy abnormal tumors as an alternative to surgical removal. Its focus is currently on early-stage breast, lung, liver and kidney tumors.
While cryoablation is not a new process, IceCure Medical’s system allows physicians to perform the procedure in their own offices, with no need for hospitalization.
The company’s ICE3 study is the largest multicenter clinical trial performing cryoablation on low-risk and early-stage breast cancer tumors.
IceCure Medical CTO and Chief Engineer Nir Berzak and IVP of Quality Assurance Shay Levav are Technion alumni.